Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: An observational study of treatment rates and clinical outcome

Israel Medical Association Journal

Volumn 10, Issue 3, 2008, Pages 214-218

  Gotsman, Israel ^a   Rubonivich, Shani ^a   Azaz Livshits, Tanya ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Angiotensin converting enzyme inhibitors; Congestive heart failure; Utilization

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRATE; RAMIPRIL; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; ISRAEL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 43249088605     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
2. Effect of enalalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991:325:29-30.
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685-91.
4. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992:327:669-77.
5. Demers C, McMurray IJ, Swedberg K, et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005;294:1794-8.
6. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag IJ, Izzo JL, Jr. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
7. Komajda M, Lapuerta P, Hermans N, et al. Adnerence to guide-lines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005;26:1653-9.
8. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL, Jr. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol 2000;86:519-23.
9. Kermani M, Dua A, Gradman AH. Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. Am J Cardiol 2000; 86-644-8.
10. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-74.
11. Chen YT, Wang Y, Radford MI, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001;141:410-17.
12. Cox JL, Ramer SA, Lee DS, et al. Pharmacological treatment of congestive heart failure in Canada: a description of care in five provinces. Can J Cardiol 2005;21:337-43.
13. Jotkowitz AB, Porath A, Shotan A, et al. Adherence to guidelines for patients hospitalized with heart failure: A nationwide survey. IMAJ 2006;8:875-9.
14. Garty M, Shotan A, Gottlieb S, et al. The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in Israel - HFSIS 2003. IMAJ 2007; 9:227-33.
15. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294:1240-7.